Please assess the completion status of the following clinical trial:

Trial Title: Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-muscle invasive transitional cell carcinoma (TCC) of the bladder (Ta, T1, Tis) recurrent after initial surgery and at least one round of adjuvant treatment (i.e. 6 weeks of intravesical biological therapy with Bacillus Calmette Guerin (BCG) solution); or~* An inability to tolerate BCG~* Age \> 18~* Eastern Cooperative Oncology Group(ECOG) Performance Status 0-2~* Laboratory tests performed within 14 days of study enrollment:~  * Leukocytes ≥ 3,200, Absolute Neutrophil count ≥ 1,500, Platelets ≥ 100,000~ * Hemoglobin ≥ 9.0 gm/dL, Total bilirubin ≤ institution upper limit of normal \*(ULN), Asparate Aminotransferase(AST) and Alanine Aminotransferase(ALT) ≤ 2.5 times ULN, Alkaline phosphatase ≤ 2.5 times ULN~ * Creatinine ≤ 1.5 times ULN~* Women of child bearing potential must have a negative pregnancy test~* If post-menopausal - Amenorrhea for ≥ 12 months~Exclusion Criteria:~* Pregnancy or breastfeeding~* Muscle invasive disease (T2-T4)~* Prior radiation to the pelvis~* Peripheral neuropathy (any grade)~* Thrombocytopenia, coagulation disorder or an increase in bleeding tendency due to other causes~* Known bladder fistula~* Hypersensitive or idiosyncratic reaction to mitomycin-C or its components in the past

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Hyperthermia system, Mitomycin C (Type: EXPERIMENTAL): Pilot study single arm study to test the safety, tolerability and clinical benefit of regional hyperthermia and mitomycin-C intravesical chemotherapy to treat non-invasive Transitional Cell carcinoma (TCC) of the bladder that has recurred after standard resection and adjuvant therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).